Mirikizumab has been approved for the treatment of moderate-to-severe ulcerative colitis . However, its efficacy and safety in treating moderately-to-severely active Crohn's disease remains unclear. A phase 3 clinical trial has investigated the effectiveness of mirikizumab in 1,150 patients with moderately-to-severely active Crohn’s disease. The study found that mirikizumab achieved a composite of patient-reported clinical response (at week 12) and endoscopic response (at week 52) in 38% of 579 patients in the treatment group compared to 9% of 199 patients in the placebo group.
Similarly, mirikizumab achieved Crohn’s Disease Activity Index clinical remission in 45.4% of 579 patients on mirikizumab compared to 19.6% of 199 patients on placebo at week 52. Notably, fewer patients reported severe adverse events in the mirikizumab group than in the ustekinumab and placebo groups. These…
